Bimeda US Launches Gamrozyne (gamithromycin) - First Bioequivalent to Zactran (gamithromycin)
Schaumburg, Illinois – Bimeda® US proudly announces the launch of GamrozyneTM, the first and only bioequivalent to Zactran® (Boehringer-Ingelheim®). This milestone expands Bimeda's robust antibiotic portfolio and offers veterinarians and producers an additional option for managing Bovine Respiratory Disease (BRD).
Gamrozyne is a fast-acting injectable macrolide antibiotic labeled for treatment of BRD in beef and non-lactating dairy cattle. Gamithromycin has been proven to reach the target lung tissue within 30 minutes and delivers 10 days of treatment with a single subcutaneous injection (Giguere S, et al. Am J Vet Res 2011; 72(3):326-330). Gamrozyne is available in 250 mL and 500 mL presentations, with a dosage of 2 mL per 110 lbs administered in the neck."Gamrozyne reinforces our commitment to delivering high-quality, cost-effective solutions to the cattle industry" said Dr Dave Ellefson, Senior Director Technical Services North America. "It joins our proven line-up of antibiotics including Macrosyn® (tulathromycin), SpectoGard® (spectinomycin) and EnroMed® (enrofloxacin), geared towards helping veterinarians and producers combat BRD.
Gamrozyne is a prescription only medication and is not for use in female dairy cattle 20 months of age and older, or in calves intended for veal production. This product has a 35-day withdrawal period.
Press Inquiries:
Erica Bord – Bimeda US Marketing - Brand Manager North America